Head-to-head · WeighScore
Henry Meds vs Mevo Health
The verdict
Henry Meds takes it — 77.3/100 to 60.2/100.
Henry Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Henry's low monthly equivalents come with a full year paid upfront, so it is a poor fit for someone shopping for a short trial.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Henry Meds | Mevo Health |
|---|---|---|
| WeighScore | 77.3/100 | 60.2/100 |
| Grade | C+ | C |
| Scorecard rank | #48 | #365 |
| Semaglutide | $197/mo (injectable; 12-month plan paid upfront in full, $2,364) | $199/mo (all doses, compounded) |
| Tirzepatide | $234/mo (compounded oral tablets; 12-month plan paid upfront in full, $2,808) | $259/mo (all doses, compounded) |
| Coverage | Multi-state | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #48 · C+
Strengths
- Published plan prices identify their upfront-payment requirement
- Medication, provider access, applicable supplies and shipping included if prescribed
- Compounded injectable semaglutide and oral options listed
Where it loses points
- The $197 semaglutide headline requires $2,364 upfront, not monthly payments
- The listed $234 tirzepatide offer is oral compounded medication, not an injectable quote
- Multi-month balances may remain payable after cancellation; medical-discontinuation refunds require documentation and approval, and dispensed medication is excluded
Graded #365 · C
Strengths
- LegitScript verification badge on multiple pages
- Publishes the FDA compounded-medication disclaimer
- Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
- Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
- Public entry-level pricing surfaced
Where it loses points
- States served not listed on any public page
- Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
- No formal Medical Director role disclosed
- Only 'as low as' entry pricing shown — no per-dose itemization
- No SOC 2 certification claimed
Also worth a look
Another provider to compare: CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.